Henriet Meems

An overview of LAG-3 as a clinically validated immunotherapy target The advent of immune checkpoint blockade (ICB) immunotherapy, pioneered by antibodies targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1)/programmed cell death protein 1 (PD-L1), has revolutionized cancer treatment by reinvigorating antitumor T-cell responses [1., 2., 3.].

The Funding section is incorrect. The correct funding information is as follows: R. Bierings and J. Voorberg were supported by funding from the Dutch Thrombosis Foundation. Citation: Smeets MWJ, Bierings R, Meems H, Mul FPJ, Geerts D, Vlaar APJ, et al. (2018) Correction: Platelet-independent adhesion of calcium-loaded erythrocytes to von Willebrand factor. PLoS ONE 13(3): e0194958. https://doi.org/10.1371/journal.pone.0194958 Copyright: © 2018 Smeets et al.

Adhesion of erythrocytes to endothelial cells lining the vascular wall can cause vaso-occlusive events that impair blood flow which in turn may result in ischemia and tissue damage. Adhesion of erythrocytes to vascular endothelial cells has been described in multiple hemolytic disorders, especially in sickle cell disease, but the adhesion of normal erythrocytes to endothelial cells has hardly been described. It was shown that calcium-loaded erythrocytes can adhere to endothelial cells.